Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Cancer immunotherapy

Deciphering the response to BCMA CAR T cell therapy

Nature Cancer volume 5, pages 1287–1288 (2024)Cite this article

Subjects

Despite the promise of chimeric antigen receptor (CAR) T cell therapy, predicting patient response is challenging. Single-cell multiomics of myeloma treated with B cell maturation antigen (BCMA)-targeted CAR T cells now reveal that poor clinical response is associated with an immunosuppressive environment and CAR T cells transition to exhausted phenotypes, indicating a mechanism for reduced persistence.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: The host’s immune milieu leads to sub-optimal responses to BCMA-directed CAR T cell therapy.

References

  1. Munshi, N. C. et al. N. Engl. J. Med. 384, 705–716 (2021).

    Article  CAS  PubMed  Google Scholar 

  2. Martin, T. et al. J. Clin. Oncol. 41, 1265–1274 (2023).

    Article  CAS  PubMed  Google Scholar 

  3. Ruella, M., Korell, F., Porazzi, P. & Maus, M. V. Nat. Rev. Drug Discov. 22, 976–995 (2023).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Rade, M. et al. Nat. Cancer https://doi.org/10.1038/s43018-024-00763-8 (2024).

    Article  PubMed  Google Scholar 

  5. Jain, M. D. et al. Blood 137, 2621–2633 (2021).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Faramand, R. et al. Clin. Cancer Res. 26, 4823–4831 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Dhodapkar, K. M. et al. Blood Cancer Discov. 3, 490–501 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Samur, M. K. et al. Blood 140, 2106–2107 (2022).

    Article  Google Scholar 

  9. Friedrich, M. J. et al. Cancer Cell 41, 711–725 (2023).

    Article  CAS  PubMed  Google Scholar 

  10. Lee, H., Neri, P. & Bahlis, N. J. Blood 143, 1211–1217 (2024).

    Article  CAS  PubMed  Google Scholar 

  11. Graham, C. E. & Maus, M. V. Blood Cancer Discov. 3, 478–480 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Cohen, A. D. et al. J. Clin. Investig. 129, 2210–2221 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  13. Alabanza, L. M. et al. Front. Immunol. 13, 832645 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Paiva, B. & San-Miguel, J. F. Nat. Cancer 4, 1534–1535 (2023).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

    Hamza Hassan & Marco L. Davila

Authors
  1. Hamza Hassan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marco L. Davila
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marco L. Davila.

Ethics declarations

Competing interests

M.L.D. receives consulting fees from Bristol Myers Squibb, Kite/Gilead, Synthekine, A2 Biotherapeutics and Adicet. M.L.D. has equity or options with Adicet, A2 Biotherapeutics and Adaptive Biotechnologies. H.H. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hassan, H., Davila, M.L. Deciphering the response to BCMA CAR T cell therapy. Nat Cancer 5, 1287–1288 (2024). https://doi.org/10.1038/s43018-024-00826-w

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-024-00826-w

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer